CCA
ALXN

Checchi Capital Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Checchi Capital Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,464
Closed -$204K – 457
2018
Q3 		$204K Buy
+1,464
New +$184K 0.02% 422
2016
Q3 		– Sell
-1,467
Closed -$171K – 1354
2016
Q2 		$171K Sell
1,467
-62
-4% -$8.8K 0.02% 389
2016
Q1 		$213K Sell
1,529
-265
-15% -$38.9K 0.05% 321
2015
Q4 		$342K Buy
1,794
+222
+14% +$38.8K 0.09% 212
2015
Q3 		$246K Buy
1,572
+105
+7% +$19.2K 0.07% 268
2015
Q2 		$265K Sell
1,467
-228
-13% -$39.3K 0.07% 259
2015
Q1 		$294K Buy
1,695
+178
+12% +$32.2K 0.09% 227
2014
Q4 		$281K Buy
1,517
+93
+7% +$17.2K 0.11% 212
2014
Q3 		$236K Buy
+1,424
New +$234K 0.1% 219

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Checchi Capital Advisers's ALXN Position: Q4 2018 in Review

Checchi Capital Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 1,464 shares — an estimated $204K sold.

Checchi Capital Advisers first reported a position in ALXN in Q3 2014 and held it in 9 quarters. The position peaked at $342K in Q4 2015. 609 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Checchi Capital Advisers reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Checchi Capital Advisers sold 1,464 Alexion Pharmaceuticals shares in Q4 2018, an estimated $204K.
  • Checchi Capital Advisers first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 9 quarters.
  • Checchi Capital Advisers's Alexion Pharmaceuticals position peaked at $342K in Q4 2015.
  • 609 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Checchi Capital Advisers's 13F filing for Q4 2018, filed 7 Feb 2019.